Trametinib

Common brands: Mekinist, Tafinlar, Opdivo, Yervoy, Pain Relief

Top reporter: Novartis Pharmaceuticals Corporation

Corticosteroid [EPC]Programmed Death Receptor-1 Blocking Antibody [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Kinase Inhibitor [EPC]CTLA-4-directed Blocking Antibody [EPC]
23,697
Total Reports
12,388
Serious Reports
5,097
Death Reports
30
Reported Reactions
Death Report Ratio: High (21.51%)

Patient Demographics

Male
10,853
Female
10,361

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Trametinib.

# Reaction Reports % of Total
1 PYREXIA 4,005
13.7%
2 DEATH 3,375
11.6%
3 MALIGNANT NEOPLASM PROGRESSION 2,013
6.9%
4 RASH 1,702
5.8%
5 FATIGUE 1,495
5.1%
6 NAUSEA 1,465
5.0%
7 CHILLS 1,272
4.4%
8 DIARRHOEA 1,263
4.3%
9 PRODUCT USE IN UNAPPROVED INDICATION 1,083
3.7%
10 VOMITING 1,050
3.6%
11 OFF LABEL USE 771
2.6%
12 HEADACHE 754
2.6%
13 ASTHENIA 719
2.5%
14 DRUG INEFFECTIVE 651
2.2%
15 MALAISE 651
2.2%
16 VISUAL IMPAIRMENT 605
2.1%
17 DECREASED APPETITE 589
2.0%
18 ARTHRALGIA 540
1.9%
19 PAIN 497
1.7%
20 DISEASE PROGRESSION 491
1.7%
21 METASTASES TO CENTRAL NERVOUS SYSTEM 484
1.7%
22 METASTATIC MALIGNANT MELANOMA 480
1.6%
23 DYSPNOEA 471
1.6%
24 MALIGNANT MELANOMA 431
1.5%
25 PNEUMONIA 418
1.4%
26 DEHYDRATION 397
1.4%
27 DIZZINESS 377
1.3%
28 VISION BLURRED 366
1.3%
29 COUGH 363
1.2%
30 CONSTIPATION 360
1.2%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.